ALPCO Launches Highly Specific FDA Class I Exempt STELLUX® Glucagon ELISA

ALPCO has announced the launch of its FDA Class I Exempt STELLUX® Chemi Glucagon ELISA. The chemiluminescence ELISA features increased specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL).

Glucagon measurements are used in the diagnosis and treatment of patients with various disorders of carbohydrate metabolism, including diabetes mellitus, hypoglycemia, and hyperglycemia. Furthermore, researchers are interested in investigating the possible connections between glucagon, pancreatic alpha cell function, and the pathophysiology of diseases such as diabetes mellitus.

“Our customers were experiencing challenges in confidently quantifying glucagon levels without cross- reactivity to oxyntomodulin, a proglucagon peptide containing the glucagon sequence known for interfering with glucagon assays,” explains ALPCO’s president, Sean Conley. “We designed our STELLUX® Chemi Glucagon ELISA to address this need and provide a more specific multifunctional tool for both diagnostic and research laboratories. We are confident this assay will empower users to further their research and improve clinical outcomes. “

The STELLUX® Chemi Glucagon ELISA is highly specific with 100% cross-reactivity to glucagon, and does not cross-react with other proglucagon peptides such as oxyntomodulin, glicentin and the incretins glucagon-like peptide-1 and stric inhibitory polypeptide. The broad range and increased specificity of the assay allows laboratories to effectively in mouse, rat, and human plasma samples. Additionally, the assay is validated for use with cell culture and is a robust tool for studying perifusion models.

For a limited time, pre-order your free STELLUX® Chemi Glucagon evaluation kit and qualify for special pricing through 2019.